KRN23

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

X-linked Hypophosphatemia (XLH)

Conditions

X-linked Hypophosphatemia (XLH)

Trial Timeline

Sep 28, 2021 → Aug 17, 2023

NCT ID

NCT04842019

About KRN23

KRN23 is a approved stage product being developed by Kyowa Kirin for X-linked Hypophosphatemia (XLH). The current trial status is completed. This product is registered under clinical trial identifier NCT04842019. Target conditions include X-linked Hypophosphatemia (XLH).

What happened to similar drugs?

1 of 7 similar drugs in X-linked Hypophosphatemia (XLH) were approved

Approved (1) Terminated (0) Active (6)

🔄KRN23Kyowa KirinPhase 3

🔄burosumab + Oral Phosphate Supplement + active vitamin DKyowa KirinPhase 3

🔄burosumabKyowa KirinPhase 3

🔄BurosumabKyowa KirinPhase 3

🔄burosumabKyowa KirinPhase 3

✅KRN23Kyowa KirinApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05357573	Approved	Completed	Sep 7, 2022	Dec 22, 2023	Tumor-Induced Osteomalacia (TIO)
NCT04842032	Approved	Completed	Nov 1, 2021	Dec 18, 2023	X-linked Hypophosphatemia (XLH)
NCT04842019	Approved	Completed	Sep 28, 2021	Aug 17, 2023	X-linked Hypophosphatemia (XLH)
NCT04308096	Phase 3	Completed	Jan 9, 2018	Dec 4, 2020	XLH
NCT03233126	Phase 3	Completed	Jul 6, 2017	Feb 17, 2020	X-linked Hypophosphatemic Rickets/Osteomalacia
NCT02722798	Phase 2	Completed	Apr 1, 2016	Oct 1, 2020	Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome
NCT02312687	Phase 2	Completed	Jan 30, 2015	Nov 30, 2018	X-Linked Hypophosphatemia
NCT02181764	Phase 1	Completed	Jul 1, 2014	Jun 1, 2015	X-linked Hypophosphatemic Rickets/Osteomalacia
NCT01571596	Phase 1/2	Completed	Feb 1, 2012	Jun 1, 2014	X-linked Hypophosphatemia
NCT01340482	Phase 1/2	Completed	Apr 1, 2011	Oct 1, 2013	X-linked Hypophosphatemia

Competing Products

20 competing products in X-linked Hypophosphatemia (XLH)

See all competitors

Product	Company	Stage	Hype Score
VK0214	Viking Therapeutics	Phase 1	26
Methylprednisolone + Prednisolone + Sirolimus	Astellas Pharma	Phase 1/2	39
Burosumab	Kyowa Kirin	Phase 1/2	32
Burosumab	Kyowa Kirin	Pre-clinical	30
Burosumab	Kyowa Kirin	Pre-clinical	26
Burosumab	Kyowa Kirin	Phase 2	35
KRN23	Kyowa Kirin	Phase 1/2	32
KRN23	Kyowa Kirin	Phase 3	40
burosumab + Oral Phosphate Supplement + active vitamin D	Kyowa Kirin	Phase 3	40
burosumab	Kyowa Kirin	Phase 3	40
burosumab	Kyowa Kirin	Phase 2	35
Burosumab	Kyowa Kirin	Phase 3	40
KRN23	Kyowa Kirin	Phase 1/2	32
Placebo + KRN23	Kyowa Kirin	Phase 1	29
Burosumab	Kyowa Kirin	Phase 3	40
burosumab	Kyowa Kirin	Phase 3	40
KRN23	Kyowa Kirin	Phase 2	35
KRN23	Kyowa Kirin	Phase 1	29
KRN23	Kyowa Kirin	Approved	43
KK8123	Kyowa Kirin	Phase 1/2	39